Gene editing approaches using CRISPR/Cas9 are being developed as a means for targeting the integrated HIV-1 provirus. Enthusiasm for the use of gene editing as an anti-HIV-1 therapeutic has been tempered by concerns about the specificity and efficacy of this approach. Guide RNAs (gRNAs) that target conserved sequences across a wide range of genetically diverse HIV-1 isolates will have greater clinical utility. However, on-target efficacy should be considered in the context of off-target cleavage events as these may comprise an essential safety parameter for CRISPR-based therapeutics. We analyzed a panel of Streptococcus pyogenes Cas9 (SpCas9) gRNAs directed to the 5′ and 3′ long terminal repeat (LTR) regions of HIV-1. We used in vitro cleavage assays with genetically diverse HIV-1 LTR sequences to determine gRNA activity across HIV-1 clades. Lipid-based transfection of gRNA/Cas9 ribonucleoproteins was used to assess targeting of the integrated HIV-1 proviral sequence in cells (in vivo). For both the in vitro and in vivo experiments, we observed increased efficiency of sequence disruption through the simultaneous use of two distinct gRNAs. Next, CIRCLE-Seq was utilized to identify off-target cleavage events using genomic DNA from cells with integrated HIV-1 proviral DNA. We identified a gRNA targeting the U3 region of the LTR (termed SpCas9-127HBX2) with broad cleavage efficiency against sequences from genetically diverse HIV-1 strains. Based on these results, we propose a workflow for identification and development of anti-HIV CRISPR therapeutics.
Get full access to this article
View all access options for this article.
References
1.
de BuhrH, LebbinkRJ: Harnessing CRISPR to combat human viral infections. Curr Opin Immunol, 2018; 54:123–129.
2.
HuW, KaminskiR, YangF, et al.: RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A, 2014; 111:11461–11466.
3.
JinekM, ChylinskiK, FonfaraI, HauerM, DoudnaJA, CharpentierE: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337:816–821.
4.
LinSR, YangHC, KuoYT, et al.: The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids, 2014; 3:e186.
5.
WangW, YeC, LiuJ, ZhangD, KimataJT, ZhouP: CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One, 2014; 9:e115987.
6.
KangH, MinderP, ParkMA, MesquittaWT, TorbettBE, SlukvinII: CCR5 disruption in induced pluripotent stem cells using CRISPR/Cas9 provides selective resistance of immune cells to CCR5-tropic HIV-1 virus. Mol Ther Nucleic Acids, 2015; 4:e268.
7.
LiuZ, ChenS, JinX. et al.: Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4(+) T cells from HIV-1 infection. Cell Biosci, 2017; 7:47.
8.
XuL, YangH, GaoY, et al.: CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Mol Ther, 2017; 25:1782–1789.
9.
PanfilAR, LondonJA, GreenPL, YoderKE: CRISPR/Cas9 genome editing to disable the latent HIV-1 provirus. Front Microbiol, 2018; 9:3107.
10.
XiaoQ, GuoD, ChenS: Application of CRISPR/Cas9-based gene editing in HIV-1/AIDS therapy. Front Cell Infect Microbiol, 2019; 9:69.
11.
Los Alamos National Laboratories, HIV sequence database. Available at https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html
12.
BbosaN, KaleebuP, SsemwangaD: HIV subtype diversity worldwide. Curr Opin HIV AIDS, 2019; 14:153–160.
13.
HemelaarJ, ElangovanR, YunJ, et al.: Global and regional molecular epidemiology of HIV-1, 1990–2015: A systematic review, global survey, and trend analysis. Lancet Infect Dis, 2019; 19:143–155.
14.
TsaiSQ, NguyenNT, Malagon-LopezJ, TopkarVV, AryeeMJ, JoungJK: CIRCLE-seq: A highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Methods, 2017; 14:607–614.
15.
AdachiA, GendelmanHE, KoenigS, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol, 1986; 59:284–291.
16.
National Center for Biotechnology Information Basic Local Alignment Search Tool. Available at http://blast.ncbi.nlm.nih.gov/Blast.cgi
17.
GibsonDG, YoungL, ChuangRY, VenterJC, HutchisonCA, 3rd, SmithHO: Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods, 2009; 6:343–345.
18.
GibsonDG: Enzymatic assembly of overlapping DNA fragments. Methods Enzymol, 2011; 498:349–361.
19.
MaliP, YangL, EsveltKM, et al.: RNA-guided human genome engineering via Cas9. Science, 2013; 339:823–826.
20.
Integrated DNA Technologies Custom Alt-R CRISPR-Cas9 guide RNA design site. Available at https://www.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM
21.
JeeningaRE, HoogenkampM, Armand-UgonM, de BaarM, VerhoefK, BerkhoutB: Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol, 2000; 74:3740–3751.
22.
KlaverB, BerkhoutB: Comparison of 5′ and 3′ long terminal repeat promoter function in human immunodeficiency virus. J Virol, 1994; 68:3830–3840.
23.
PlattEJ, BilskaM, KozakSL, KabatD, MontefioriDC: Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol, 2009; 83:8289–8292.
24.
PlattEJ, WehrlyK, KuhmannSE, ChesebroB, KabatD: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol, 1998; 72:2855–2864.
25.
TakeuchiY, McClureMO, PizzatoM: Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol, 2008; 82:12585–12588.
26.
WeiX, DeckerJM, LiuHet al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother, 2002; 46:1896–1905.
27.
DerdeynCA, DeckerJM, SfakianosJN, et al.: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol, 2000; 74:8358–8367.
28.
GuschinDY, WaiteAJ, KatibahGE, MillerJC, HolmesMC, RebarEJ: A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol, 2010; 649:247–256.
29.
Tsai lab respository for CIRCLE-seq analytical software. Available at https://github.com/tsailabSJ/circleseq
30.
DoenchJG, FusiN, SullenderM, et al.: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol, 2016; 34:184–191.
31.
GeonnottiAR, BilskaM, YuanX, et al.: Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. AIDS Res Hum Retroviruses, 2010; 26:279–291.
32.
SullivanNT, DampierW, ChungCH, et al.: Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients. Sci Rep, 2019; 9:17088.
33.
RoychoudhuryP, De Silva FeelixgeH, ReevesDet al.: Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. BMC Biol, 2018; 16:75.
HsuPD, ScottDA, WeinsteinJA, et al.: DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol, 2013; 31:827–832.
36.
WangZ, WangW, CuiYC, et al.: HIV-1 employs multiple mechanisms to resist Cas9/single guide RNA targeting the viral primer binding site. J Virol, 2018; 92:e01135–18.
37.
DasAT, BindaCS, BerkhoutB: Elimination of infectious HIV DNA by CRISPR-Cas9. Curr Opin Virol, 2019; 38:81–88.
38.
LebbinkRJ, de JongDC, WoltersF, et al.: A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci Rep, 2017; 7:41968.
39.
DarcisG, BindaCS, KlaverB, Herrera-CarrilloE, BerkhoutB, DasAT: The impact of HIV-1 genetic diversity on CRISPR-Cas9 antiviral activity and viral escape. Viruses, 2019; 11:255.
40.
WangG, ZhaoN, BerkhoutB, DasAT: A combinatorial CRISPR-Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected T cell cultures. Cell Rep, 2016; 17:2819–2826.
ZischewskiJ, FischerR, BortesiL: Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. Biotechnol Adv, 2017; 35:95–104.
43.
AkcakayaP, BobbinML, GuoJA, et al.: In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature, 2018; 561:416–419.
44.
BaeS, ParkJ, KimJ: Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics, 2014; 30:1473–1475.
45.
CameronP, FullerCK, DonohouePD, et al.: Mapping the genomic landscape of CRISPR-Cas9 cleavage. Nat Methods, 2017; 14:600–606.
46.
HaddenJM, ConveryMA, DéclaisA-C, LilleyDMJ, PhillipsSEV: Crystal structure of the Holliday junction resolving enzyme T7 endonuclease I. Nat Struct Biol, 2001; 8:62–67.
47.
HsiauT, ConantD, MauresT, et al.: Inference of CRISPR edits from Sanger trace data. Available at https://www.biorxiv.org/content/biorxiv/early/2019/01/14/251082.full.pdf accessed on August11, 2020.
48.
BrinkmanEK, ChenT, AmendolaM, van SteenselB: Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res, 2014; 42:e168.
49.
van RossumG, DrakeFLJr: Python Reference Manual. Centrum voor Wiskunde en Informatica, Amsterdam, 1995.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
